contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


anders-hultman-will-be-stepping-down-as-ceo-of-idl-diagnostics

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

IDL Diagnostics är specialiserade inom onkologi och bakteriologi. Bolaget har en bred produktportfölj, och utvecklar, marknadsför och säljer blod-, och urin provtester som används av sjukhus och kliniker. Testerna ämnar ge information för upptäckt av sjukdomar såsom urologiska cancerformer och tyfoidfeber. IDL Diagnostics riktar sig till patientgrupper i olika delar av världen. Huvudkontoret ligger i Stockholm.

IDL Diagnostics              Article - IDL Diagnostics    [et_pb_section fb_built=”1″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.4″...                             IDL Diagnostics har säkrat sin första kommersiella order för TPS CLIA från sin japanska partner, ett ledande globalt japanskt IVD-företag, för utplacering på den kinesiska marknaden.

Från och med idag är namnet IDL Diagnostics AB                   IDL Diagnostics              IDL Diagnostics | Saving lives with diagnostics    IDL Diagnostics ell is a Swedish diagnostics companywith the vision to improve the monitoring of oncological and bacterial diseases.                             Jag uppdaterade rubriken. Ny ticker är IDLDX

AroCell 3.0 föreslås vid årsstämman:  The board proposes to the annual general meeting (AGM) that AroCell AB changes its name to IDL Diagnostics AB. The main purpose of the name change is to create a stronger connection to the diagnostics industry.             storage.mfn.se              arocells-board-of-directors-proposes-to-the-agm-that-the-parent-company-change-its-name-to-idl-diagnostics-ab.pdf

Riktningen är tydligt rätt. Detta * Includes costs for goodwill amortization of KSEK 39,578 (39,578) for the period.* förvånar, resultatet skulle ju vara rejält positivt men den där årliga “avskrivningen” spökar fortfarande i siffrorna, vad fan är det?

Arocells Q4-rapport publicerad. Jag knappade snabbt in siffrorna i Excel och det verkar gå åt rätt håll.  Allt som allt ett ganska bra kvartal: bästa hittills när det gäller omsättning, första EBITDA-positiva och när det gäller kassaflödet redan det andra positiva kvartalet (senast Q2-24).

Det här meddelandet hamnade nog i fel företags tråd, eftersom länken öppnar en artikel om Arise AB?

Och idag kom tydligen det kinesiska patentgodkännandet

IDL Diagnostics

The Board of Directors of IDL Diagnostics AB (publ) (“IDL Diagnostics”) and CEO Anders Hultman have today agreed that Anders will be leaving his role as CEO of IDL Diagnostics.“Anders Hultman...

<div class="mfn-preamble"><p><strong>The Board of Directors of IDL Diagnostics AB (publ) (“IDL Diagnostics”) and CEO Anders Hultman have today agreed that Anders will be leaving his role as CEO of IDL Diagnostics.</strong></p></div><div class="mfn-body"><p>“Anders Hultman has, during his five years as CEO of IDL Diagnostics, led the company in a commendable manner. He has strengthened the company’s position and positioned it for continued growth, including through the acquisition and merger of AroCell and IDL Biotech, as well as by developing our sales channels and partnerships. Under Anders’ leadership, IDL Diagnostics has become the company it is today; the board believes that now is the right time for new leadership to guide IDL Diagnostics towards increased profitability and continued growth,” says Max Pihlqvist, Chairman of the Board.</p><p>“I have had the privilege of working at the company for more than seven years, five of which as CEO. During this period, the company has undergone significant changes, not least through the acquisition of IDL Biotech. Over the past five years, sales have almost tripled while we have strengthened the organisation. We have also broadened our product portfolio through the formation of a joint venture that will be of great importance for our ability to grow in new markets. The company is well equipped to take the next step in its growth journey,” says Anders Hultman, outgoing CEO.</p><p>Anders will continue in his current role during a transitional period. The board will now begin the process of recruiting a new CEO.</p></div><div class="mfn-footer mfn-contacts mfn-d7431fd42f58"><p><strong class="mfn-heading-1">Contacts</strong></p><hr><p>Max Pihlqvist, Chairman of the Board<br>Phone: +46 42 32 40 16<br>Email: max.pihlqvist@labex.com</p></div><div class="mfn-footer mfn-about mfn-3400a8a23fe3"><p><strong class="mfn-heading-1">About IDL Diagnostics</strong></p><hr><p>IDL Diagnostics AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. IDL Diagnostics' product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. IDL Diagnostics (IDLDX) is listed on Nasdaq First North Growth Market with Redeye Sweden AB as company's Certified Adviser. For more information; <a rel="noopener" href="https://arocell.us12.list-manage.com/track/click?u=afc00720b3f14956d7aa211ee&amp;id=b0c0db8833&amp;e=1eac5f4714">www.idldiagnostics.com</a></p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that IDL Diagnostics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-03-05 08:30 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/16060ff4-0142-42ab-a417-7fda1fe7126a/anders-hultman-will-be-stepping-down-as-ceo-of-idl-diagnostics.pdf" class="mfn-generated mfn-primary">Anders Hultman will be stepping down as CEO of IDL Diagnostics</a></p></div>